CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Combined Positive Score for Programmed Death Ligand-1 Expression and Inflammatory Microenvironment in Gastrointestinal Stromal Tumors.
Combined Positive Score for Programmed Death Ligand-1 Expression and Inflammatory Microenvironment in Gastrointestinal Stromal Tumors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
GISTs 是消化道最常见的间叶性肿瘤类型。预后主要取决于肿瘤尺寸、核分裂率和位置,但其他记录较少的因素也可影响演变和生存。免疫微环境和检查点分子表达已被证明可影响不同类型癌症的预后。本研究旨在确定 GISTs 中 PD-L1 的表达,并评估瘤内免疫浸润水平与预后变量及生存的关系。
对 2015 年至 2018 年间在同一机构诊断的 65 例 GISTs 进行 PD-L1 免疫组化检测,并使用 CPS 进行评估。重点观察免疫细胞,使用 CD3、CD4、CD8、CD20 和 CD68 抗体并对其进行定量。所有数据均使用统计工具处理。
中位年龄为 61 岁(范围,28-78),36 例患者(55.4%)为男性。肿瘤位置主要为胃(46%),其次为小肠(17%)和结直肠(6%)。此外,11% 为 EGISTs,20% 为继发性肿瘤(11% 转移和 9% 局部复发)。PD-L1 在肿瘤细胞和炎性细胞中表达不一,CPS 范围为 0 至 100。此外,64.6% 的病例为 PD-L1 阳性,在患者年龄和性别、肿瘤位置、肿瘤的原发性或继发性特征、尺寸、核分裂率、疾病进展风险和肿瘤细胞类型等变量类别之间无显著差异。免疫细胞在整个肿瘤中分布不一。CD3+ 淋巴细胞是最常见的类型。在 ≤5 cm 的肿瘤中鉴定出更多数量的 CD20+ 细胞(p = 0.038)。PD-L1阳性肿瘤与PD-L1阴性肿瘤相比,免疫细胞数量更多,尤其是CD3+、CD20+和CD68+细胞(p = 0.032,p = 0.051,p = 0.008)。上皮样和混合细胞型肿瘤的CD68+细胞数量更高。生存率不受PD-L1表达的影响;相反,在多灶性肿瘤中(p = 0.0001)以及Ki67 ≥ 50%的病例中(p = 0.008),生存率降低。
PD-L1阳性表达以及不同免疫细胞类型以不同数量存在,有助于更好地理解肿瘤细胞与微环境之间复杂的相互作用,并可能在GISTs中具有治疗价值。
Background and Objectives : GISTs are the most frequent type of mesenchymal neoplasm of the digestive tract. The prognosis is mainly determined by tumor dimensions, mitotic rate and location, but other less well-documented factors can influence evolution and survival. The immune microenvironment and checkpoint molecule expression were proven to impact the prognosis in different types of cancer. The aim of this study was to determine PD-L1 expression in GISTs and to evaluate the level of intratumoral immune infiltration in relation to prognostic variables and survival.
Materials and Methods : Sixty-five GISTs diagnosed in the same institution between 2015 and 2018 were immunohistochemically tested for PD-L1 and evaluated using CPS. Immune cells were emphasized, with CD3, CD4, CD8, CD20 and CD68 antibodies and quantified. All data were processed using statistical tools. Results : The median age was 61 years (range, 28-78) and 36 patients (55. 4%) were males. The location of the tumors was predominantly gastric (46%), followed by the small bowel (17%) and colorectal (6%).
In addition, 11% were EGISTs and 20% were secondary tumors (11% metastases and 9% local recurrences). PD-L1 had a variable expression in tumor and inflammatory cells, with a CPS ranging from 0 to 100.
Moreover, 64. 6% of cases were PD-L1 positive with no significant differences among categories of variables, such as the age and the sex of the patient, tumor location, the primary or secondary character of the tumor, dimensions, mitotic rate, the risk of disease progression and tumor cell type. Immune cells had a variable distribution throughout the tumors. CD3+ lymphocytes were the most frequent type. CD20+ cells were identified in a larger number in tumors ≤5 cm ( p = 0. 038). PD-L1-positive tumors had a higher number of immune cells, particularly CD3+, CD20+ and CD68+, in comparison to PD-L1-negative ones ( p = 0.
032, p = 0. 051, p = 0. 008). Epithelioid and mixed cell-type tumors had a higher number of CD68+ cells. Survival was not influenced by PD-L1 expression; instead, it was decreased in multifocal tumors ( p = 0. 0001) and in cases with Ki67 ≥ 50% ( p = 0. 008). Conclusions : PD-L1-positive expression and the presence of different immune cell types, in variable quantities, can contribute to a better understanding of the complex interactions between tumor cells and the microenvironment, with a possible therapeutic role in GISTs.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。